By competing with the co-stimulatory molecule CD226 for binding to the ligand CD155, TIGIT inhibits the CD226-mediated T cell activation signal, thereby weakening T cell cytokine secretion and proliferation capacity (66, 67), in addition to its combination with PD-1 inhibitors in anti-tumor therapy, recent studies have found that combined blockade of CD47 and TIGIT targets can enhance the phagocytic activity of macrophages against leukemia in vitro. This evidence concerns the gene TIGIT and neoplasm.